Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (42)COVID-19 (36)

Type

TypeGuidance (4054)Indicators (310)News (285)NICE advice (496)Quality standards (252)Research recommendations (1913)

Status

StatusAwaiting development (354)Discontinued (434)In consultation (6)In development (372)Published (2512)Topic selection (344)

Last updated

Last updatedLast 3 months (171)Last 6 months (276)Last year (466)Last 3 years (1519)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (25)Cancer service guidelines (10)Clinical guidelines (380)COVID-19 NHSE/I specialty guides (2)COVID-19 rapid guidelines (27)Diagnostics guidance (93)Health technology evaluations (50)Highly specialised technologies guidance (48)Interventional procedures guidance (981)Medical technologies guidance (150)Medicines practice guidelines (5)NICE guidelines (565)Public health guidelines (89)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2163)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)

Showing 7261 to 7275 of 7964 results

Sort by

Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued [GID-TA10228]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]
Discontinued [GID-TA10233]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]
Discontinued [GID-TA10234]
Result type
Technology appraisal guidance
Status
Discontinued
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
Discontinued [GID-TA10236]
Result type
Technology appraisal guidance
Status
Discontinued
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
Discontinued [GID-TA10242]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab for previously treated endometrial cancer [ID1205]
Discontinued [GID-TA10243]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued [GID-TA10244]
Result type
Technology appraisal guidance
Status
Discontinued
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued [GID-TA10254]
Result type
Technology appraisal guidance
Status
Discontinued
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Discontinued [GID-TA10259]
Result type
Technology appraisal guidance
Status
Discontinued
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
In development [GID-TA10261] Expected publication date: TBC
Result type
Technology appraisal guidance
Status
In development
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]
Discontinued [GID-TA10264]
Result type
Technology appraisal guidance
Status
Discontinued
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
Discontinued [GID-TA10267]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
Discontinued [GID-TA10271]
Result type
Technology appraisal guidance
Status
Discontinued
Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
Discontinued [GID-TA10277]
Result type
Technology appraisal guidance
Status
Discontinued
Eltrombopag for untreated severe aplastic anaemia [ID1198]
Discontinued [GID-TA10284]
Result type
Technology appraisal guidance
Status
Discontinued

Previous page
1
…
483
484
Current page 485
486
487
…
531
Page 485 of 531
Next page

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Knowledge resources

About NICE
Into practice
Get involved with NICE
Jobs
News
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.